Merosin-deficient congenital muscular dystrophy type 1A (MDC1A) is a dramatic neuromuscular disease in which crippling muscle weakness is evident from birth. Here, we use the dy W mouse model for human MDC1A to trace the onset of the disease during development in utero. We find that myotomal and primary myogenesis proceed normally in homozygous dy WÀ/À embryos. Fetal dy WÀ/À muscles display the same number of myofibers as wildtype (WT) muscles, but by E18.5 dy WÀ/À muscles are significantly smaller and muscle size is not recovered post-natally. These results suggest that fetal dy WÀ/À myofibers fail to grow at the same rate as WT myofibers. Consistent with this hypothesis between E17.5 and E18.5 dy WÀ/À muscles display a dramatic drop in the number of Pax7-and myogenin-positive cells relative to WT muscles, suggesting that dy WÀ/À muscles fail to generate enough muscle cells to sustain fetal myofiber growth. Gene expression analysis of dy WÀ/À E17.5 muscles identified a significant increase in the expression of the JAK-STAT target gene Pim1 and muscles from 2-day and 3-week old dy WÀ/À mice demonstrate a dramatic increase in pSTAT3 relative to WT muscles. Interestingly, myotubes lacking integrin a7b1, a laminin-receptor, also show a significant increase in pSTAT3 levels compared with WT myotubes, indicating that a7b1 can act as a negative regulator of STAT3 activity. Our data reveal for the first time that dy WÀ/À mice exhibit a myogenesis defect already in utero. We propose that overactivation of JAK-STAT signaling is part of the mechanism underlying disease onset and progression in dy WÀ/À mice. † These authors contributed equally to this work.
Introduction
Merosin-deficient congenital muscular dystrophy (CMD) type 1A (MDC1A), or laminin-a2 CMD (LAMA2-CMD), is a devastating neuromuscular disease in which patients demonstrate hypotonia from birth. Human MDC1A was initially described by Tomé et al. and is caused by mutations in the LAMA2 gene (1) (2) (3) , which encodes the laminin a2 chain of laminins 211 and 221 (4) . Laminin 211 is the predominant laminin isoform in the basement membrane surrounding adult muscle fibers, while laminin 221 localizes specifically to neuromuscular junctions (5, 6) . Laminin 211 is crucial for myofiber survival (7, 8) , and is involved in the regulation of the autophagy-lysosome pathway and the ubiquitin-proteasome system (9, 10) .
It is generally believed that the absence of laminin 211 around myofibers in MDC1A patients causes a constant stress on these cells, which progressively damages them, inducing muscle wasting, inflammation and fibrosis (11) . Since infants are already affected at birth, the muscle weakness underlying the disease must already have arisen during development in utero. However, it is unclear when and how disease begins in MDC1A.
Mouse skeletal muscle development starts at E8.5 when Pax3-and/or Pax7-positive muscle stem cells at the edges of the dermomyotome are induced to initiate the myogenic program and differentiate into myotomal myocytes (12) (13) (14) . The myogenic program involves the expression of one or more of the myogenic regulatory factors (MRFs), the transcription factors Myf5, MyoD, Mrf4 and myogenin (15) . From E11.5 until E14.5, these myocytes fuse with differentiating primary myoblasts giving rise to primary (embryonic) myofibers of the trunk muscles, while dermomyotome-derived Pax3-positive cells have migrated and differentiate into the primary myofibers of limbs, tongue and diaphragm (16) (17) (18) (19) (20) . Subsequently, from E14.5 until birth, Pax7-positive muscle stem cells within the muscle masses undergo a second wave of differentiation into secondary myoblasts. These myoblasts then use the primary myofibers as a scaffold and fuse with each other, generating secondary (fetal) myofibers, and subsequently fuse with both primary and secondary myofibers, increasing their size (17, 20) . Thus fetal skeletal muscle grows both by addition of new myofibers (hyperplasia) and by fusion of myoblasts to existing myofibers, increasing their size (cell-mediated hypertrophy).
Laminins 111 and 511 are thought to play a role in early stages of myogenesis in the somites (21) and laminins 211, 411 and 511 are found in fetal muscles (5) . However, little is known about the exact assembly dynamics and specific roles of the different laminin isoforms during myogenesis. It has been suggested that a4-and a5-laminins can compensate for the absence of a2-laminins during myogenesis in utero (5, 22) , but this hypothesis has not been formally tested.
Here, we perform a detailed analysis of the assembly dynamics of the different laminin isoforms during normal mouse skeletal muscle development. We then use the dy W mouse model for MDC1A to study the effect of laminin a2-chain deficiency on skeletal muscle development in vivo. We demonstrate that myotomal and primary myogenesis proceed without defects in dy WÀ/À embryos. However, during secondary myogenesis, dy WÀ/À muscles exhibit impaired growth, fail to maintain the normal number of Pax7-positive muscle stem cells and experience a dramatic drop in the number of myogenin-positive myoblasts. This dy WÀ/À muscle defect correlates with an overactivation of JAK-STAT signaling as well as a dysregulation of Myostatin signaling which we suggest hampers the amplification of the pool of mononucleated muscle cells necessary for cell-mediated hypertrophy of myofibers. We show for the first time that MDC1A starts before birth in dy WÀ/À mice and that the onset of the disease in utero is marked by impaired fetal myogenesis.
Results
Myotomal and primary myogenesis proceed normally in dy WÀ/À embryos Our first aim was to detect the stage of MDC1A onset during mouse development. We first characterized myotome development in E10.5 dy WÀ/À embryos. Immunostaining (for n numbers;
see Supplementary Material, Tables S1 and S2) with a panmuscle laminin antibody demonstrates that the laminin matrices lining the dermomyotome and the myotome are normal in dy WÀ/À embryos (Fig. 1A , A 0 , C and C 0 ). The mouse Lama2 gene is normally expressed by myotomal myocytes (Fig. 2D and F) and laminin a2 chain localizes to the myotomal basement membrane in a similar pattern to laminin a1 and a5 chains ( Fig. 2A , B, E 0 and G 0 ). Laminin a1 and a2 chains are also detected in a patchy pattern among myotomal myocytes ( Fig. 2A, E 1N ; n ¼ 3À6 per genotype). In fact, our analysis of laminin deposition during primary myogenesis (E11.5-E13.5) in normal embryos supports this hypothesis.
Immunostaining with pan-muscle laminin antibody ( Fig. 2H and H 0 ) (23, 24) and with antibodies for a2 (Fig. 2I ), a1 and a5 chains (data not shown) failed to detect a laminin-containing basement membrane around primary myotubes. These results indicate that primary myogenesis is normally laminin independent (see Fig. 3P ). These data show that myotome development and primary myogenesis are not significantly affected in dy WÀ/À embryos.
Laminins 411 and 511 line myofibers and Pax7-positive cells in fetal dy WÀ/À muscles
We next determined the normal dynamics of laminin assembly during fetal muscle development by immunohistochemistry. Laminin assembly around myofibers starts at E14.5 ( Fig. 3A) , i.e. precisely at the beginning of secondary myogenesis (17) . In agreement with, and expanding on the data by Patton et al. (5), we find that laminin assembly around myofibers involves Table S2 for n numbers. NT, neural tube. Dorsal is on the left. Scale bars: 50 lm.
laminins containing the a2, a4 and a5 chains ( Fig. 3B-D) , while laminin a1 is absent (data not shown; see Fig. 4C ). The myofiber basement membrane is discontinuous at E14.5 ( Fig. 3A-D) , but then grows progressively in subsequent stages (E15.5: Fig. 3E -H and M; E17.5: Fig. 3I -L). Pax7-positive muscle stem cells are reported to enter their niche under the myofiber basement membrane at around E16.5 (25, 26) . Consistent with this notion, we observed a progressive increase in laminin coverage near Pax7-positive cells between E15.5 ( Fig. 3N , N 0 and N 00 ) and E17.5 ( Fig.   3O , O 0 and O 00 ). Thus during normal fetal myogenesis, laminins 211, 411 and 511 are gradually assembled around myofibers (see Fig. 3P ) and by E17.5 most Pax7-positive muscle stem cells reside underneath the myofiber basement membrane. It has previously been suggested that laminin a4 and a5 chains may play a role in compensating for the absence of a2 chain laminins during development (5, 22) . Indeed, at E17.5 these two laminin chains are detected around both WT and dy WÀ/À myofibers (Fig. 4A , B, E and F). The laminin a1 chain, (27, 28) . The localization of the a7 subunit of the a7b1 integrin ( Fig. 4D and H) and the a-subunit of dystroglycan ( Fig. 4I and J epaxial muscles. n!3 fetuses/pups per genotype/stage and staining, except for a7 integrin (n¼2 per genotype) and laminin a2 (n¼1 per genotype). LNa2, laminin a2.
Dorsal is to the left and medial is up. Scale bars: 100 lm (A-J); 50 lm (K-O 00 ).
Material, Fig. S1A Fetal dy WÀ/À muscles fail to fully expand their pool of
Pax7-positive muscle stem cells and generate fewer differentiated myoblasts
To address the cellular mechanism behind the impaired muscle growth in dy WÀ/À fetuses, we used immunohistochemistry for Pax7 and myogenin in sections of WT and dy WÀ/À fetuses and PN2 pups to detect muscle stem cells and differentiated myoblasts, respectively. During normal WT fetal myogenesis, there is a steady increase in the number of Pax7-positive cells in the muscle masses between E15.5 and E17.5 ( Fig. 5M ; gray line), and the number of Pax7-positive cells stays stable between E17.5 and E18.5 ( Fig. 5M ; gray line). This occurs even though this pool of cells also feeds into the myogenin-positive pool through differentiation ( Fig. 5N ; gray line). Quantification of the number of Pax7-and myogenin-positive cells shows that these are at first normal in dy WÀ/À muscles ( Fig. 5M and N; black lines), but between E17.5 and E18.5 there is a dramatic reduction in the number of both Pax7-and myogenin-positive cells in dy WÀ/À ( Fig. 5M and N; black lines) compared with WT muscles ( Fig. 5M and N dy WÀ/À muscles display an overactivation of the
JAK-STAT signaling pathway
We next applied an RT-qPCR approach to assess for potential changes in the following signaling pathways known to be modulators of muscle growth: Wnt/b-catenin (29, 30) , Notch (31-34), JAK-STAT (35) (36) (37) and Myostatin (GDF8) (38) (39) (40) (41) . These experiments were done on muscles isolated from E17.5 fetuses, i.e. immediately before dy WÀ/À muscles are significantly different from WT muscles in terms of a cross-sectional area and the number of Pax7-and myogenin-positive cells. We did not detect significant differences in transcript levels of the Wnt signaling target genes Axin2 and Wisp1 in dy WÀ/À when compared with WT fetal muscles (Fig. 6A) . Transcript levels of the Notch target genes Dll1, HeyL and Hey1 were also not different between dy WÀ/À and WT muscles (Fig. 6B) . However, transcripts for the JAK-STAT signaling target gene Pim1 were significantly increased ( Fig. 6C ; a 42% increase; P ¼ 0.007) in dy WÀ/À muscles, while Bcl6 and Myc were unchanged (Fig. 6C) .
Finally, the Myostatin signaling target gene Akirin1, which is negatively regulated by Myostatin (42), was significantly increased in dy WÀ/À compared with WT muscles ( Fig. 6D ; a 27%
increase; P ¼ 0.027). Cdkn1a, which encodes for p21 and can be regulated by Myostatin signaling (40) , demonstrates a slight, but not significant, increase in transcript levels in dy WÀ/À fetuses (Fig. 6D) . Together, these results point to the possibility that an overactivation of the JAK-STAT signaling pathway and a downregulation of the Myostatin signaling pathway in E17.5 dy WÀ/À muscles may underlie the myogenesis defect identified at E18.5.
To test this hypothesis further, we quantified the amount of phosphorylated STAT3 (Tyr 705) (pSTAT3) in E17.5 back muscles using SureFire analysis. This assay revealed that dy WÀ/À back muscles have, on average, more pSTAT3 compared with control muscles, but this difference was not statistically significant ( Fig.  6E ; P ¼ 0.131; n ¼ 4-6 per genotype group). We then isolated protein from the back muscles of PN2 pups and performed Western blot analysis for pSTAT3 (Tyr 705). The results revealed a 3.4-fold and statistically significant (P ¼ 0.002) increase in pSTAT3 levels in dy WÀ/À compared with WT muscles (Fig. 6F) .
Furthermore, pSTAT3 levels remain significantly higher in 3-week old dy WÀ/À compared with WT muscles ( Fig. 6H ; P ¼ 0.012).
Together, these data demonstrate that dy WÀ/À muscles display a significant increase in JAK-STAT signaling from very early on, possibly as early as E17.5, and that pSTAT3 activity remains significantly higher in the muscles of 3-week old dy WÀ/À mice.
Inflammatory cells and fibrotic tissues are known to secrete cytokines that may augment JAK-STAT signaling (43) . However, fetal and PN2 dy WÀ/À muscles were morphologically normal at all stages studied ( and did not display any infiltration of macrophages at E17.5 or PN2 (as assessed by CD11b immunolabeling; data not shown) nor any increase in Sirius Red staining at PN2 (data not shown). Thus, these results exclude inflammation and fibrosis as the reason for the increased pSTAT3 activity detected in E17.5 and PN2 dy WÀ/À muscles.
Interestingly, mature Myostatin protein levels were also significantly increased (2.1-fold; P ¼ 0.049) in PN2 dy WÀ/À muscles when compared with WT ( Fig. 6F) indicating that, unlike at E17.5 where our RT-qPCR results indicate a reduction in Myostatin signaling, at PN2 mature Myostatin protein is upregulated in dy WÀ/À muscles.
Laminin 211 is known to bind to and signal through the a7b1 integrin receptor (44, 45) . To assess whether the a7b1 integrin modulates the JAK-STAT and/or Myostatin signaling pathways, we measured pSTAT3 and mature Myostatin levels in a7 À/À and control a7 þ/þ myoblasts and myotubes. No significant differences were detected between a7 À/À and a7 þ/þ myoblasts (Fig.   6G ). Mature Myostatin levels were also not significantly different in a7 À/À compared with a7 þ/þ myotubes (Fig. 6G) . However, pSTAT3 levels were dramatically increased (3.1-fold; P < 0.0001) in a7 À/À myotubes compared with a7 þ/þ myotubes (Fig. 6G ).
These results demonstrate that whereas the a7b1 integrin does not appear to affect JAK-STAT signaling in myoblasts, it is a potent negative regulator of JAK-STAT signaling in myotubes. Together, these results implicate increased pSTAT3 activity in early stages of dy WÀ/À pathology through a mechanism that seems to involve the a7b1 integrin on myotubes. Moreover, we also provide evidence for a dysregulation of Myostatin signaling in dy WÀ/À compared with WT muscles as Myostatin signaling is reduced in dy WÀ/À fetal muscles masses but then mature
Myostatin levels are increased in these muscles after birth.
Discussion

MDC1A starts during development in utero in the dy WÀ/À mouse model
Here we reveal for the first time that MDC1A in the dy WÀ/À mouse starts during development in utero. Although laminins containing the a2-chain are first detected during myotome development, this phase of myogenesis proceeds normally in dy WÀ/À embryos. Laminin 111 and 511 are present during myotome development (this study, 5,21) and we find that both laminin a1 and laminin a2 are detected within the E10.5 myotome, suggesting laminin 111 is able to compensate for the absence of laminin 211 in the myotome. Consistent with this hypothesis, overexpression of a laminin a1 transgene (46) and laminin 111 protein therapy ameliorate pathology in laminin a2-deficient mice (47, 48) . Strikingly, primary myogenesis appears to proceed in the total absence of assembled laminins both in trunk and limbs (this study, 23) suggesting that this phase of myogenesis is laminin-independent. Accordingly, we verified that primary myogenesis proceeds normally in dy WÀ/À embryos.
Laminin assembly around myotubes resumes at E14.5, at the very beginning of secondary (fetal) myogenesis, with the assembly of laminins 211, 411 and 511, but not laminin 111 (this study, 5). We find that these laminins progressively come to line myofibers and Pax7-positive muscle stem cells as they enter their niche at around E16.5 (25, 26, 49) . Fetal myogenesis is characterized by intense muscle growth, which occurs in two ways: (1) by the generation of secondary myofibers (hyperplasia) most of which occurs until E18.0 (26) and (2) through growth of these secondary myofibers, as well as the preexisting primary myofibers, through fusion of myoblasts to these fibers (cell-mediated hypertrophy) (17, 20 Fig. 7A and C) . Our results also show that E18.5 dy WÀ/À fetal muscles have an even more dramatic reduction in myogenin-positive cells. This suggests that E18.5 dy WÀ/À fetal muscles also experience an impaired generation of normal numbers of differentiated and fusion-competent myoblasts. However, increased JAK-STAT signaling leads to an increase in MyoD levels (35) (36) (37) 56) . A possible explanation may lie in the concomitant and significant upregulation of Akirin1 (Mighty) in dy WÀ/À muscles at E17.5.
Akirin 1 is negatively regulated by Myostatin signaling and is known to activate MyoD in satellite cells (40, 42, 57) . Normally, committed myoblasts can undergo one or two cell divisions before MyoD activates p21, inducing cell cycle exit (58) . Interestingly, Mstn À/À fetuses exhibit a drop in the number of Pax7-and myogenin-positive cells at E18.5, which the authors suggest is due to an overactivation of MyoD in committed cells, leading to their faster exit from the cell cycle and formation of muscles. This may occur due to an increase in the frequency of asymmetric cell divisions at the expense of amplifying symmetric divisions (A 0 and C 0 ), either because of altered laminin composition (absence of laminin 211) and/or an increase in pSTAT3 activity (A 0 and C 0 ). Consequently, E18.5 dy WÀ/À muscles would have fewer Pax7-positive muscle stem cells than WT muscles (A 00 and C 00 ). We further propose that, due to an increased expression of Aikirin1 (A 0 and C 0 ), committed cells in fetal dy WÀ/À muscles would display impaired expansion capacity, leading to fewer terminally differentiated myoblasts (A 00 and C 00 ; shaded cells in C 00 would not be generated).
Therefore, E18.5 dy WÀ/À muscles have fewer myogenin-positive, terminally differentiated myoblasts than WT muscles (A 00 and C 00 ). In normal postnatal muscle, the fre- fewer differentiated and fusion-competent cells (41) . We thus suggest that the drop in myogenin-positive cells observed in E18.5 dy WÀ/À muscles may be due to an attenuation of Myostatin signaling which makes committed cells differentiate faster and without significant amplification ( Fig. 7A and C) . Taken together we propose a model for MDC1A onset ( Fig.  7A and C) where the absence of laminin 211 around fetal myofibers and/or an overactivation of JAK-STAT signaling shift the balance of muscle stem cell divisions to asymmetric divisions, leading to a reduction in the renewal rate of the Pax7-positive muscle stem cell pool. Furthermore, the simultaneous attenuation in Myostatin signaling inhibits the normal amplification of committed cells, leading to a drop in the number of myogenin-positive cells, formation of fewer fusion-competent myoblasts and, consequently, an impairment in fiber growth. Indeed, a gradual drop in Pax7-positive cell numbers is known to occur during normal postnatal development with the progressive increase in the frequency of asymmetric cell divisions (59) . Moreover, muscle stem cells experience a change in identity between fetal and postnatal stages of development, where their capacity for self-renewal goes down while the potency to either differentiate or to recolonize the satellite cell niche increases (60) . Our data show that fetal dy WÀ/À muscles experience a premature decrease in the number of Pax7-positive cells suggesting that they make the transition to a postnatal identity too early. PN2 pups show a significant increase in pSTAT3 activity ( Fig.  7B and D) , suggesting that continuous laminin 211-integrin a7b1 signaling is normally required to dampen this signaling pathway. Curiously, in contrast to the situation observed at E17. 5 where Myostatin signaling appears to be attenuated, dy WÀ/À PN2 muscles display higher levels of mature Myostatin compared with WT muscles (Fig. 7B and D) . The reason for this is unclear, but a simultaneous increase in pSTAT3 and Myostatin is characteristic of aged muscle, and is thought to be a major factor in the observed loss of regeneration potential during muscle aging (61, 62) . Consistent with this notion, the muscles of dy WÀ/À mice have a dramatic reduction in regeneration capacity (48, 63) . We therefore propose that dy WÀ/À muscles display an aged phenotype where, at each time-point from fetal development to adulthood, the muscle environmental cues resemble that of substantially older muscles.
Conclusions
In the present study, we provide the first evidence of in utero defects in a mouse model for MDC1A. This marks a paradigm shift in our understanding of MDC1A disease pathogenesis because rather than putting deteriorating muscle fiber health as a first step in the disease, our data demonstrate that the primary defect in dy WÀ/À mice arises because of impaired in fetal myogenesis. Our results also uncovered the relevance of JAK-STAT and Myostatin pathways in dy WÀ/À disease onset and progression, which emphasizes the importance of these pathways as targets for future therapies. Taken together, our study provides an important framework for future in utero therapies and highlights the necessity for prenatal disease diagnosis and early intervention.
Materials and Methods
Mice and genotyping 
Cell culture
Myoblasts isolated previously from gastrocnemius muscles of 10-day old a7bgal þ/þ and a7bgal À/À mice (65) were cultured in six-well plates until confluence in Dulbecco's modified Eagle medium (DMEM) (GIBCO) supplemented with 20% fetal bovine serum (Atlanta Biologicals), 0.5% chick-embryo extract (Seralab), 2 mM L-glutamine (GIBCO) and penicillin/streptomycin (100 U/ ml; GIBCO) at 37 C with 5% CO 2 . Myotubes were obtained by differentiating a7bgal þ/þ and a7bgal À/À myoblasts during 5 days in DMEM supplemented with 1% horse serum (Atlanta Biologicals), 2mM L-glutamine (GIBCO) and penicillin/streptomycin (100 U/ ml; GIBCO).
In situ hybridization
To determine the mRNA expression pattern of Lama2 (66), E10.5 embryos were fixed in 4% paraformaldehyde (PFA) in PBS for whole mount in situ hybridization as described previously (66) . Briefly, embryos were hybridized overnight at 70 C and probe localization was detected with alkaline phosphataseconjugated anti-dioxygenin antibodies and NBT/BCIP (Roche) as a substrate. The number of embryos used is listed in Supplementary Material, Table S1 .
Immunohistochemistry
Embryos were fixed in 0.2% PFA in 0.12M phosphate buffer (PB) overnight at 4 C. Fetuses and PN2 pups were fixed in 2% PFA in PB for 2 days at 4 C. Embryos, fetuses and PN2 pups were cryoembedding and 12 lm cryosections were processed for immunohistochemistry essentially as in Bajanca et al. (67) . However, cryosections of fetuses and PN2 pups were incubated with 0.2% Triton X-100 in PBS for 20 min at room temperature before blocking with 5% bovine albumin serum in PBS. Antigen retrieval was done in E15. Table  S4 . The polyclonal antibody against EHS-laminin (i.e. laminin 111) (4) detects all laminins containing a1, b1 or c1 chains (68) . Since all laminin isoforms in skeletal muscle contain at least the c1 chain, we used this polyclonal anti-laminin antibody to detect all muscle laminins and designate it pan-muscle laminin antibody. TUNEL assay was performed using DeadEnd Fluorometric TUNEL System (Promega). DNA was visualized with 4,6-diamidino-2-phenylindole (DAPI, 5 mg/ml, Sigma). The number of embryos, fetuses and PN2 pups processed for immunohistochemistry and/or TUNEL assay are listed in Supplementary Material, Tables S1 and S2.
Whole mount immunohistochemistry
Whole mount immunohistochemistry was performed as described previously (69) . Briefly, dissected fetal back muscles were incubated with primary and secondary antibodies for 2 days at 4 C and were washed for a full day after each antibody incubation. For nuclear staining fetal muscles were incubated with Topro3 (T3605; Molecular Probes; 1:400) and 10 mg/ml ribonuclease A (55674; Calbiochem; 1:100) together with the secondary antibodies. Antibodies used are listed in Supplementary Material, Table S4 .
SureFire
AlphaLISA SureFire Ultra kit for p-STAT3 (Tyr705) (ALSU-PST3-A500) was performed according to the manufacturer's instructions (Perkin Elmer). Ten micrograms of protein extract were used per sample for this assay.
Western blotting
Protein extracts were collected in radioimmunoprecipitation assay buffer (RIPA) with 5 mM NaF, 10 mM Na 3 VO 4 and a protease inhibitor cocktail (Thermo Scientific; 1:500) and stored at À80 C. After quantification using Pierce BCA protein assay kit (Thermo Scientific), protein extracts were separated with SDS 10 or 12% polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Signals were detected using 
Real time quantitative RT-PCR
RNA was extracted from E17.5 back muscles with Trizol Reagent kit (Ambion, Life Technologies). First-strand cDNA synthesis was performed using the SuperScript III First-Strand Synthesis System for RT-PCR kit (Ambion, Life Technologies). Real-Time qPCR reactions were performed in triplicates with 2Â PowerUp SYBR Green Master Mix (Life Technologies) and 500 ng RNA. Transcript levels were normalized against Gapdh expession and the fold change was calculated using DDCt method. Primers used are listed in Supplementary Material, Table S5 .
Image analysis and quantifications
Sections processed for in situ hybridization were photographed using an Olympus DP50 camera coupled to an Olympus BX51 microscope. Sections processed for immunohistochemistry were either imaged with a Hamamatsu Orca R2 camera coupled to an Olympus BX60 fluorescence microscope, or images were acquired on an Olympus IX81 or Leica SPE confocal microscope system. The acquired images were analyzed in Fiji version 1.49 and imported to Amira V.5.3.3 (Visage Imaging, Inc.) software as described previously (69, 70) . Transverse sections processed for immunohistochemistry were used for muscle cross-sectional area measurements and quantification of total myofibers, primary myofibers, Pax7-and myogenin-positive cells. To ensure maximum standardization, quantifications were always done in three specific epaxial muscle groups (transversospinalis, longissimus and iliocostalis) at forelimb level and three to five sections per staining and embryo/fetus/PN2 pup were used. Overlapping confocal images covering the three specific epaxial muscles were obtained with a 20Â lens and individual images were then stitched together into a large composite image (see Supplementary Material, Fig.  S1 ) using the Fiji plugin Pairwise Stitching (71) . Areas were measured using a drawing tool to line the muscles in Fiji and quantifications were performed using Fiji plugin Cell Counter (http://fiji.sc/Cell_Counter). We consider the sum of the number of Pax7-and myogenin-positive cells as a close estimate for the total number mononucleated muscle cells in the muscle masses (Supplementary Material, Table S3 ) (20) . All measurements and counts were done in a blinded fashion.
Statistical analysis
Student's t-test was used to test for differences between mRNA, protein or pSTAT3 levels in muscle samples from WT and dy WÀ/À fetuses and/or PN2 pups, and a7 þ/þ and a7 À/À cells, considering P < 0.05 as statistically significant. Student's t-test was also used to test for differences in the number of Pax7-and myogenin-positive cells in sections of WT and dy WÀ/À muscles.
Finally, differences in muscle cross-sectional area and myofiber numbers were tested using a nested ANOVA where individuals were nested within genotypes (WT or dy WÀ/À ). As described above, all parameters were quantified in stitched composite images of three to five sections per individual, each section covering the same three muscle groups. Each stage was tested separately. Statistical analyses were performed using GraphPad Prism 5 and STATISTICA 12 software.
Supplementary Material
Supplementary Material is available at HMG online.
